Digoxin-specific antibodies: a novel dosing strategy
Publication date
2024-02
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Digoxin-specific antibodies (digoxin-Fabs) are of value in the treatment of a strongly suspected or a known, potentially life-threatening digoxin toxicity. These antibodies are not registered for use in Europe; therefore Dutch hospital pharmacies are not allowed to keep them in stock. In the Netherlands, digoxin-Fabs are stored in a national calamity stock of emergency medicines at the National Institute for Public Health and the Environment. In the case of a medical emergency, digoxin-Fabs are available after contact with the Dutch Poisons Information Centre. Recent studies have shown that the dose of digoxin-Fabs required to effectively treat digoxin toxicity is lower than previously thought. In this article, we present the adjusted digoxin-Fab dosing strategy currently recommended by the Dutch Poisons Information Centre ( www.vergiftigingen.info ). This new dose titration strategy is safe and effective and has a cost-saving side-effect.
Keywords
Antidote, Digoxin poisoning, Digoxin-specific antibodies, Cardiology and Cardiovascular Medicine, Journal Article, Review
Citation
Dijkman, M A, Gresnigt, F M J & de Lange, D W 2024, 'Digoxin-specific antibodies : a novel dosing strategy', Netherlands Heart Journal, vol. 32, no. 2, pp. 70-73. https://doi.org/10.1007/s12471-023-01814-y